Reuptake of L‐DOPA‐derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter
Citations Over TimeTop 15% of 2008 papers
Abstract
To determine the role of norepinephrine transporter in reuptake of L-DOPA-derived extracellular DA in the DA-denervated Parkinsonian striatum, we examined extracellular DA levels in the striatum of 6-hydroxyDA-lesioned rats that received L-DOPA (50 mg/kg with 12.5 mg/kg of benserazide) and L-DOPA plus desipramine (25 mg/kg), a selective norepinephrine reuptake inhibitor, using in vivo microdialysis. The pretreatment with desipramine increased levels of extracellular DA derived from administrated L-DOPA in the DA-denervated striatum. This study provides evidence that L-DOPA-derived DA is taken up by the norepinephrine transporter, instead of the dopamine transporter, in the striatum with dopaminergic denervation. This result suggests that the norepinephrine transporter could be a promising target in the treatment for Parkinson's disease.
Related Papers
- → Enhanced norepinephrine output during long-term desipramine treatment: A possible role for the extraneuronal monoamine transporter (SLC22A3)(2007)21 cited
- → Development of norepinephrine transporter reuptake inhibition assays using SK-N-BE(2)C cells(2018)3 cited
- → Thiophene derivatives: a new series of potent norepinephrine and serotonin reuptake inhibitors(2002)14 cited
- → Aldosterone augments Na+-induced reduction of cardiac norepinephrine reuptake(2014)3 cited
- → Antidepressant-sensitive norepinephrine transporters: structure and regulation(2023)